Form 4: Avidity Biosciences Director Jean Jinsun Kim Reports Stock Option Grant

Director Jean Jinsun Kim reports acquisition of stock options in Avidity Biosciences.

Summary

• Jean Jinsun Kim, a director of Avidity Biosciences, Inc., reported a transaction involving derivative securities.
• On June 13, 2024, Kim acquired stock options for 13,489 shares of common stock at an exercise price of $39.96.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board.
• Following the transaction, Kim directly owns 13,489 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Key Dates